Repeat of: A Study to Evaluate Efficacy and Safety of Sublingual TNX-102 SL Tablet Taken at Bedtime in Patients With Fibromyalgia

ClinicalTrials.gov ID: NCT02829814

Public ClinicalTrials.gov record NCT02829814. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.

View official ClinicalTrials.gov record → Back to search

ClinicalTrials.gov public records Last synced Jul 22, 2026, 3:42 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Official title

A Phase 3, Double-Blind, Randomized, Multicenter, Placebo-Controlled Study To Evaluate The EFFIcacy and Safety of TNX-102 SL Tablets Taken Daily At Bedtime In Patients With FibRoMyalgia

Study identification

NCT ID: NCT02829814
Recruitment status: Terminated
Study type: Interventional
Phase: Phase 3
Lead sponsor: Tonix Pharmaceuticals, Inc.; Industry
Enrollment: 51 participants

Conditions and interventions

Conditions

Interventions

TNX-102 SL Tablet, 2.8 mg Drug
Placebo SL Tablet Drug

Drug

Eligibility (public fields only)

Age range: 18 Years to 75 Years
Sex: All
Healthy volunteers: Healthy volunteers not accepted

This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.

Study timeline

Start date: Jul 21, 2016
Primary completion: Sep 12, 2016
Completion: Sep 12, 2016
Last update posted: Feb 24, 2025

2016

United States locations

U.S. sites: 32
U.S. states: 20
U.S. cities: 31

Facility	City	State	ZIP	Site status
Not listed	Birmingham	Alabama	35216	—
Not listed	Phoenix	Arizona	85032	—
Not listed	Oceanside	California	92056	—
Not listed	San Diego	California	92103	—
Not listed	Brandon	Florida	33511	—
Not listed	DeLand	Florida	32720	—
Not listed	Ocala	Florida	34471	—
Not listed	Orlando	Florida	32801	—
Not listed	Tampa	Florida	33613	—
Not listed	Tampa	Florida	33614	—
Not listed	West Palm Beach	Florida	33409	—
Not listed	Evansville	Indiana	47714	—
Not listed	Indianapolis	Indiana	46260	—
Not listed	Jackson	Mississippi	39202	—
Not listed	Las Vegas	Nevada	89102	—
Not listed	Cedarhurst	New York	11516	—
Not listed	Williamsville	New York	14221	—
Not listed	Raleigh	North Carolina	27612	—
Not listed	Fargo	North Dakota	58103	—
Not listed	Canton	Ohio	44718	—
Not listed	Cincinnati	Ohio	45219	—
Not listed	Medford	Oregon	97504	—
Not listed	Portland	Oregon	97210	—
Not listed	Salem	Oregon	97301	—
Not listed	Allentown	Pennsylvania	18104	—
Not listed	Warwick	Rhode Island	02888	—
Not listed	Mt. Pleasant	South Carolina	29464	—
Not listed	Chattanooga	Tennessee	37421	—
Not listed	Dallas	Texas	75231	—
Not listed	Salt Lake City	Utah	84102	—
Not listed	Seattle	Washington	98104	—
Not listed	Kenosha	Wisconsin	53142	—

Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.

About this trial record page

What this page shows: Public field values for ClinicalTrials.gov record NCT02829814, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
What this page does not do: No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
Where the data comes from: Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
Last refresh: Last update posted Feb 24, 2025 · Synced Jul 22, 2026

Open the official record

The complete protocol, eligibility criteria, and contact information for NCT02829814 live on ClinicalTrials.gov.

View official ClinicalTrials.gov record →